Reference207 articles.
1. Abdollahi, A., Lipson, K.E., Sckell, A., et al. 2003. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890–8898.
2. Albanell, J., Royo, F., Auerbach, S., et al. 2002. Pharmacokinetic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histological and molecular consequences of receptor inhibition. J Clin Oncol 20:110–124.
3. Alsina, M., Fonseca, R., Wilson, E.F., et al. 2004. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103:3271–3277.
4. Baker, M.J., Brem, S., et al. 2002. Complete response of a recurrent, multicentric malignant glioma patient treated with phenylbutyrte. J Neurooncol 59:239–242.
5. Barnett, F.H., Scharer-Schuksz, M., Wood, M., et al. 2004. Intra-arterial delivery of endostatin gene to in tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther.11:1283–1289.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献